Introduction
Platelets are critically involved in the pathophysiology of coronary thrombosis and atheroprogression. 1, 2 Beyond classical platelet activation cascades, oxidized lipid metabolites [e.g. oxidized LDL (oxLDL)] promote platelet activation and thrombogenicity by stimulating tissue factor release and thromboinflammation. 3, 4 Dyslipidaemia is associated with coronary atherothrombosis 3, 4 ;
. however, the contribution of platelets to lipid metabolism in coronary artery disease (CAD) is poorly defined. In acute coronary syndrome (ACS) patients, platelets exhibit enhanced oxLDL binding that correlates with their activation status. 5 OxLDL binds to scavenger receptors on platelets (e.g. CD36) 4, 6 and enhances NOX-2-mediated generation of reactive oxygen species (ROS) and platelet hyperreactivity. 7 In ACS, oxLDL enhances coronary atherosclerosis by promoting cellularity, macrophage activation, and differentiation into foam cells, substantiating smooth muscle cell proliferation and decreasing endothelial nitric oxide (NO) production. 8, 9 Plasma oxLDL status detected by E06 antibody, anti-oxLDL autoantibody titres, LDL-autoantibody immune complexes (ICs) show significant elevation following myocardial infarction (MI) in ACS patients. 8 Recently plasma levels of specific long-chain ceramides and their ratios were validated as more effective prognostic markers for cardiovascular mortality in stable CAD and ACS patients than established biomarkers-LDL-cholesterol or C-reactive protein (CRP). 10 However, circulating oxidized phospholipids (oxPL)/apolipoprotein B (apoB), immunoglobulin G (IgG)-IgM-autoantibodies to oxLDL, and IgG-IgM-apoB-IC in stable angina pectoris (SAP) patients fail to predict the occurrence of restenosis, 9 necessitating further evaluation of peripheral biomarkers. Oxidized lipids can influence platelet activation, apoptosis, inflammatory association with monocytesmacrophages, which is governed by platelet-derived CXCL12, acting differentially through CXCR4-CXCR7 to prompt atheroprogression. 11 Although platelet-lipid associations are acknowledged accomplice in atherosclerosis, 2,3 a lipidomic evaluation of the circulatory platelet compartment in CAD remained unexplored. Chemokines and their receptors influence inflammation in atherosclerosis. 12 Platelets are a major source of chemokines (e.g.CXCL12)
that are released upon activation and regulate autocrine and paracrine functions in the microenvironment of thrombi. 13 Plateletderived CXCL12 (SDF-1) and its cognate receptors CXCR4 and CXCR7 are enhanced in ACS and are associated with myocardial functional recovery and long-term prognosis following MI. 14 Recently, CXCR7 was shown to regulate cholesterol uptake in adipose tissue, thereby ameliorate hyperlipidaemia and atheroprogression in ApoE À/À mice. 15 Therefore, it was worthwhile exploring the impact of CXCL12 in influencing platelet-lipid association, its functional consequences in CAD, whereby plasma levels of CXCL12 are elevated and platelets show increased surface expression of CXCR7. 14 In the present study, we explored the significance of intraplatelet lipid metabolism by a lipidomics approach in patients with symptomatic CAD and disclosed the impact of platelet-CXCL12 and CXCR-4/-7 on lipid-induced pro-oxidative and prothrombotic functions of platelets.
Materials and methods
Detailed descriptions are provided in Supplementary material online.
Study subjects and patients
We included 175 consecutive patients with symptomatic CAD from the TUEPIC clinical registry and 15 healthy volunteers ( Tables 1 and 2) . Baseline characterististics of subjects enrolled for intraplatelet oxLDL analysis are presented in Table 1 ; those of matched controls, SAP, and STEMI patients included for lipidomic analysis are presented in Table 2 .
The study was approved by the institutional ethics committee (270/ 2011BO1) and complies with the declaration of Helsinki and good clinical practice guidelines. 14 All patients gave written informed consent. Blood samples were collected from arterial femoral access site during coronary angiography and processed as described in Supplementary materials online, Methods. Healthy volunteers agreed to donate blood samples for scientific purpose, did not present with any obvious disease symptoms, and were free of medication at the time of blood sampling. n = 15; male, n (%) = 7 (46%); age, mean ± SD = 30 ± 7 years.
Statistical analysis Experimental
Data (mean ± SD) were analysed using GraphPad Prism software (GraphPad Software, Inc., San Diego, CA, USA) at P < 0.05 statistical significance with one-way analysis of variance using Tukey's post hoc test.
Clinical cohort
Data (mean ± SD) were analysed using SPSS version 21.0 (SPSS, Inc., Chicago, IL, USA). Non-normally distributed data were compared using the Mann-Whitney U test. Correlations of non-normally distributed data were assessed by Spearman's rank correlation coefficient (q).
Correlations of normally distributed data were analysed using Pearson's correlation coefficient (r). Mean Fluorescence Intensity (MFI)s are presented as median values with 25th and 75th percentiles. 14 
Lipidomics
Raw data from ultrahigh-performance liquid chromatographyelectrospray ionization-quadrupole time-of-flight-tandem mass spectrometry (UHPLC-ESI-QTOF-MS/MS) analysis (Sciex wiff files) were imported into MS-DIAL 16 and preprocessed before statistical analysis (peak alignment, noise filtering, internal standard and LOWESS normalization, and structure annotation). Preprocessed data (normalized peak areas) were exported from MS-DIAL and used for univariate and multivariate analysis. Normalized peak areas were log-transformed and subjected to unpaired Student's t-test to identify peaks varying significantly (P < _ 0.05). To account for the problem of multiple hypothesis testing, a
Translational perspective false discovery rate (FDR) controlling procedure was further adopted to correct significance levels for FDR < _ 5% (Supplementary material online, Table S1 shows fold changes, P-and Q-values; calculated using Bioconductor software). Multivariate statistical analysis was performed using MarkerView (Sciex). Normalized peak areas were log-transformed and autoscaled before they were subjected to principal component analysis-discriminant analysis (PCA-DA) ( Figure 1 , See Supplementary material online, Figure S1 ). Statistically significant differences of medians of Box plots were evaluated by Mann-Whitney U test.
Results
Platelet-oxLDL levels are elevated in coronary artery disease and correlate with CXCR7 surface expression Table 1 ) when compared with the healthy subjects (n = 15; Figure 2A ). Platelet-oxLDL positively correlated with CXCR7 surface expression and inversely with CXCR4 ( Figure 2B) . To evaluate the significance of CXCR4-CXCR7 and their ligand on lipid uptake, human platelets were incubated in vitro with fluorochrome-labeled oxLDL-LDL in the presence/ absence of recombinant (r) CXCL12 and blocking anti-CXCR-4/-7 monoclonal antibodies (mAbs; Figure 2C ). rCXCL12 enhanced both oxLDL and LDL uptake in a CXCR4-and CXCR7-dependent manner ( Figure 2C ). rCXCL12 mediated enhancement in oxLDL-LDL uptake could be attributed to increased surface exposure of scavenger receptors CXCL16-SR-PS/OX and AporER2 on platelets in the presence of rCXCL12 (See Supplementary material online, Figure S2 ). Moreover, oxLDL-LDL increased surface exposure of CXCL12 ( Figure 2D ) and differentially modulated CXCR4 and CXCR7 surface expression in vitro, decreasing CXCR4 while enhancing CXCR7 surface exposure ( Figure 2D ). Similar differential regulation of both receptors had been shown by CXCL12. 17 oxLDL-LDL-induced dynamic regulation of relative surface expression of CXCR4/CXCR7 as observed in vitro substantiates the positive correlation between platelet-oxLDL-CXCR7 and an inverse relation with CXCR4 in CAD patient cohort.
LDL uptake triggers reactive oxygen species-mediated intraplatelet lipid oxidation/peroxidation
Previously, nicotinamide adenine dinucleotide phosphate-oxidase (NADPH oxidase)-generated ROS was shown to oxidize LDL extracellularly in activated platelet supernatant. 18 We also found that LDL-oxLDL triggered intracellular ROS and intraplatelet mitochondrial superoxide (MitoSOXred-sensitive) production ( Figure 3A) . Further, LDL-oxLDL promoted lipid peroxidation ( Figure 3A) . This indicates that LDL-oxLDL alters the intracellular redox status of 18 and that platelets contribute to (per)oxidative lipid modifications. Therefore, intracellular levels of oxLDL were enhanced in parallel to LDL uptake, suggesting intraplatelet oxidative conversion of LDL ( Figure 3B ). Both oxidative conversion ( Figure 3C ) and intraplatelet lipid peroxidation ( Figure 3D ) were significantly inhibited by a cell-permeable SOD2-mimetic MnTMPyP, scavenging superoxide, indicating that mitochondrial superoxide might drive lipid oxidation in platelets.
Lipid profile of circulating platelets is significantly altered in coronary artery disease
To characterize the potential of platelets for lipid metabolism, we analysed resting platelet extracts from a group of matched control (MC), SAP, and STEMI patients ( Table 2) , by lipidomics profiling using UHPLC-ESI-QTOF-MS/MS using data-independent acquisition with SWATH 16, 19 (See Supplementary material online, Table S2 ). The preprocessed (aligned, normalized, and logtransformed) data were subjected to supervised PCA-DA with the different samples as objects and the preprocessed molecular features as factors. Samples with similar lipid profiles were clustered closely together in the resultant score plot of PCA-DA, which clearly illustrates significant differences in platelet lipid profiles between MC (n = 11), SAP (n = 10), and STEMI (n = 13) ( Figure 1A) . Details of lipidomics data analysis are available in Supplementary date. To figure out lipids that are significantly up-/ down-regulated in CAD patient samples in comparison with MCs, t-tests were used. Among 1038 structurally annotated lipids with significantly altered abundances between STEMI and MC (unadjusted P < _ 0.05), 172 lipids were identified by manual revision of spectrometric data in MS-DIAL and LipidBlast database and selected to create a heat map ( Figure 1B) . We found strikingly elevated levels of triglycerides (TG), PLC metabolite diacylglycerol (DG), phosphatidylcholine (PC), plasmenyl-PCs (p-PC), and sphingomyelin (SM) in STEMI patients in comparison with MCs. The lipids with FDR < _ 5% are given in Supplementary material online, Table S1 .
Free radical-induced oxidation of membrane phospholipids (PLs) might generate complex mixtures of oxPLs. 20 Several oxPLs, e.g. 20 were elevated in SAP and were significantly increased in STEMI patients when compared with MC ( Figure 1Ci ). This could be attributed to enhanced oxidative stress and platelet hyperreactivity in STEMI patients which could influence intraplatelet oxidative lipid modification into oxPL. Figure S3 ) were altered in STEMI samples, when compared with MC. Alterations in circulatory carnitine and acylcarnitine levels in CAD patients are suggestive of impaired carnitine homeostasis in ischaemic myocardium. Plasma levels of medium-and long-chain acylcarnitines have differential predictive potential for mortality and or/MI. 21 Currently, we detected elevated levels of medium (14:1) and long-chain acylcarnitines (18:2) in platelets from SAP and STEMI patients whrn compared with MC. Levels of both showed significant increase in STEMI in comparison with SAP group (Figure 1Cvii) . Therefore, intraplatelet acylcarnitines along with plasma carnitines and troponin could be considered as additional peripheral biomarker strategy in risk stratification. 
LDL-oxLDL-induced reactive oxygen species generation enhances platelet functions
Hyperlipidaemia propagates platelet activation and thrombosis. 3, 4, 6 Currently, we defined the impact of LDL-oxLDL-induced intracellular ROS generation on platelet functions. LDL-oxLDL enhanced a IIb b 3 -integrin activation (PAC1) and degranulation (CD62P) ( Figure 4A ), significantly inhibited by the SOD2-mimetic MnTMPyP ( Figure 4B) .
Moreover, LDL-oxLDL triggered platelet apoptosis ascertained by enhanced thrombogenic phosphatidylserine exposure (annexin V binding) ( Figure 4C ) and mitochondrial membrane depolarization (Dwm-TMRE) (See Supplementary online, Figure S4 ), corroborating with mitochondrial superoxide generation. LDL-oxLDL-induced apoptosis was comparable to that induced by conventional platelet agonists like CRP, thrombin receptor-(PAR1)-activating peptide TRAP ( Figure 4C , See Supplementary material online, Figure S4 ), which was also inhibited by MnTMPyP ( Figure 4D , Supplementary material online, Figure S4 ). Further, LDL-oxLDL significantly augmented platelet-dependent thrombin generation in human PRP in vitro in response to tissue factor (See Supplementary material online, Figure S5 ) and aggregation response to TRAP (See Supplementary material online, Figure S6) . Similarly, LDL-oxLDL administration to mice in vivo altered plasma coagulation profile (activated partial thromboplastin time-aPTT) as subsequently ascertained ex vivo ( Figure 4E) . Consequently, LDL-oxLDL induced thrombus formation over collagen in ex vivo flow chamber assay ( Figure 4F ) with human blood, also thrombotic response in vivo among ferric chloride-induced occlusive thrombosis model in mice. Following Dil-LDL/Dil-oxLDL administration, thrombus formation was enhanced in injured carotid artery, showing significantly reduced time-to-vessel occlusion ( Figure  4G) . The gradual accumulation of fluorescent Dil-LDL/Dil-oxLDL along with platelet-specific marker GPIb, as evident in the overlay images during thrombus build-up, ( Figure 4G ) suggested LDL-oxLDLloaded platelets being associated with thrombosis.
CXCL12 enhances the thrombotic effects of oxLDL-LDL
CXCL12 is a prothrombotic chemokine. 22 CXCL12 enhanced LDLoxLDL-induced ROS generation ( Figure 5A ), degranulation (CD62P), and a IIb b 3 -integrin activation ( Figure 5B) . Effect of CXCL12 combined with LDL/oxLDL on platelet morphology dynamics was investigated using single-cell live imaging of human platelets (SICM) 23 ( Figure 5Ca-e) .
CXCL12 synergistically augmented LDL-oxLDL-induced morphological changes to a more irregular shape within minutes of administration, indicating a rapid and significant activation of platelets in response to LDL-oxLDL (Figure 5Ca -d, Supplementary material online, Figure  S7 ). LDL-oxLDL effect on platelet spreading over collagen-coated surfaces was similar (See Supplementary material online, Figure S8 ). LDL-oxLDL-induced platelet-dependent thrombus formation and enhanced prothrombotic CXCL12 release from platelets. In the presence of neutralizing anti-CXCL12 or blocking anti-CXCR4 mAbs, oxLDL-induced thrombus formation was significantly attenuated ( Figure  5D) . Further, recombinant(r)CXCL12 supplementation enhanced oxLDL-induced thrombus formation ex vivo (See Supplementary material online, Figure S9 ). Although rCXCL12 administration to mice in vivo increased thrombotic occlusion, a combination of CXCL12-oxLDL did not influence it further (See Supplementary material online, Figure S10) . These evidences indicate a synergistic impact of the CXCL12/CXCR4 axis on lipid-associated thrombosis.
Elevated platelet-oxLDL is associated with thrombotic functions
Next, we verified the potential association between platelet-oxLDL status and prothrombotic function. Hyperlipidaemic ldlr À/À mice showed significantly enhanced levels of circulatory platelet-oxLDL ( Figure 6A ) and correspondingly enhanced thrombus formation ex vivo when compared with their wild-type littermates ( Figure 6B ), indicating enhanced thrombotic function. Correspondingly, in ACS patients with angiographic evidences of intracoronary thrombus, circulating platelet-oxLDL status was significantly elevated [oxLDL median MFI 21.5 Figure 6C ). This indicates an association between elevated plateletoxLDL status and thrombotic function. Moreover, ex vivo analysis of intracoronary thrombi sections showed substantial oxLDL deposition in platelet-rich areas ( Figure  6D and E) specified by platelet-specific CD42b abundance ( Figure  6D ). This corroborates with enhanced platelet-oxLDL status in STEMI patients with intracoronary thrombi and taken together signifies circulatory platelet-oxLDL as an enriched lipid depository at thrombi. Similarly, deposition of chemotactic CXCL12 ( Figure 6E ) in thrombi possibly accounted for the presence of proinflammatory CD68 þ macrophages, (See Supplementary material online, Figure S11 ), and the presence of CXCR7 in intracoronary thrombus section along with oxLDL corroborates the positive correlation between platelet-oxLDL and CXCR7 expression in platelets from CAD patients.
Discussion
The major findings of the study are the following: (i) platelet-oxLDL levels are significantly elevated in CAD patients, correlate positively with platelet CXCR7 surface expression, and is primarily associated with STEMI; (ii) LDL-induced ROS generation triggers intraplatelet oxidative conversion into lipid peroxides, oxidized metabolites, which corroborates with prevalence of oxPLs in CAD patients exhibiting altered platelet lipidome (e.g. enhanced di-and tri-acylglycerols, CEs, ceramides, SMs, acylcarnitines); and (iii) CXCL12 enhances LDL-oxLDL uptake and synergistically augments LDL-oxLDLinduced pro-oxidative and prothrombotic platelet functions through CXCR-4/-7. Platelets are a major compartment for intracellular lipid metabolism in CAD patients. Platelet lipidome is associated with but distinct from plasma lipid profile (Table 2) , which is modulated by the CXCL12/CXCR4-CXCR7 axis ( Figure 6F ). This novel dynamic interplay between CXCL12-CXCR4-CXCR7 and platelet lipid association might be of pathophysiological relevance in CAD patients. OxLDL orchestrates initiation and progression of atherosclerosis, while lipid-enriched ruptured plaques trigger atherothrombosis and ischaemic occlusions. 3, 8, 9, 20 OxLDL/oxidized lipid metabolites in plaques are derived from degraded foam cells at atheromatous core. 20 Platelets interact with lipids; however, the significance of platelet lipid metabolism and its functional consequences in CAD remained unclear. Serum levels of lipids have been reported as risk factors for CAD. 10, 24, 25 Presently, we show that platelets are a significant compartment for lipid metabolism in CAD. Platelets take up plasma lipids, which might change intraplatelet lipid profile through further intracellular oxidative and enzymatic modifications. We defined distinct lipid metabolites such as oxPLs, CEs, acylcarnitines, SMs, and ceramides 
that exhibit differential levels at baseline (without further activation ex vivo) in platelets from STEMI patients when compared with MCs. Most patients in the cohort had normal plasma total cholesterol profile (Tables 1 and 2) ; however, elevated platelet-CEs. This suggests a unique dynamics between serum/plasma lipids and the intraplatelet pool, resulting from intracellular lipid modifications. Platelet lipidome is influenced by plasma lipid association and their activation status even in healthy subjects. 26 Only recently prognostic value and association between plasma ceramides and cardiovascular mortality have been validated in both stable CAD and ACS patients over conventional plasma lipid markers (e.g. LDL-cholesterol) in three independent CAD cohorts. 10 Plasma levels of certain ceramides are enhanced in ACS. 10 We found identical ceramides present in platelets, at significantly elevated levels in CAD patients as compared with MC. 
Simultaneously increased SM levels, suggests up-regulation in sphingolipid catabolism in CAD patients possibly due to platelet hyperreactivity. Platelet activation is accompanied by ceramide and sphingosine-1-phosphate release causing a dynamic alteration in blood sphingolipids levels. Therefore, a significant enhancement in sphingolipid metabolism resulting in increased platelet Cer (d18:1/ 16:0) levels as currently observed in SAP-STEMI patients is of relevance. Thus, circulating platelets can generate reactive lipids with atherogenic potential 20 under hyperlipidaemic conditions.
Pro-inflammatory oxidized lipids induce endothelial dysfunction, monocyte/macrophage differentiation, plaque growth, subsequent plaque instability, and ischaemic complications. 3, 8, 9, 20 OxPLs in modified LDL and oxLDL, and their protein adducts, are involved in diverse cardiovascular pathophysiologies. 20 OxPLs during early atherogenic progression activate pro-inflammatory genes substantiating inflammatory cascades in the vessel wall, are also detected in advanced atherosclerotic lesions, promote thrombosis by activating platelets through scavenger receptor CD36 and platelet-activating factor receptor (PAFR), 4, 20 besides induce expression of pro-coagulant tissue factor (TF), and additionally counteract tissue factor pathway inhibitor (TFPI). 4, 20 The functional significance of intraplatelet oxPL in regulating platelet functions, thereby disease severity in ACS remains to be ascertained. OxLDL constitutes an array of metabolites resulting from oxidative modifications of both lipid and protein components, which provides diverse immunogenic oxidation-specific epitopes 20 . Currently, an elevation in circulatory platelet-oxLDL and its moderate correlation with CXCR7-CXCR4 as detected by anti-oxLDL antibody and flow cytometry was further substantiated by enhanced levels of several oxidized lipid metabolites, as analysed by an extensive, untargeted, but more sensitive lipidomics analysis. OxPLs formed upon LDL oxidation are preferentially transferred to lipoprotein(a) in plasma, making them accessible to lipoprotein-PLA2 and are degraded into lysoPC and oxidized free fatty acids. 20 cPLA2 pathway is highly active in platelets in their prothrombotic state 26, 27 . Recently, heterogeneity of the platelet lipidome was demonstrated in three genetically unrelated healthy subjects, 26 which undergoes significant alteration following thrombin stimulation in vitro. During this, cPLA2 regulates lipid flux into mitochondria, where they serve as substrates for b-oxidation to yield acetyl CoA for the citric acid cycle energy drive. 26 Moreover, thrombin-induced changes in lipidomic profile in healthy subjects are counteracted by aspirin supplementation. 26 These recent evidences signified the much-warranted evaluation of platelet lipidome in CAD patients with hyperactive platelets in circulation. Enhanced intraplatelet acylcarnitine levels suggest mitochondrial fatty acid oxidation 26 involving conversion of long-chain acyl-CoAs to acylcarnitines by carnitine palmitoyltransferase-1 located at the outer mitochondrial membrane. Thus platelets might contribute to acylcarnitine levels in plasma. PLA2 metabolite Lyso PC16:2 showed enhanced levels while some lysoPEs (e.g. lysoPE 18:1 and lysoPE 20:1) are decreased (See Supplementary material online, Table S1 ), which could arise as they are reacylated to PLs in the Land's cycle by acyl-CoA:lysophospholipid acyltranferase activity and further lead to the generation of oxPLs. 26 Although how intraplatelet oxidized lipid metabolites might influence disease severity remains unascertained, current evidence suggest that intraplatelet lipid processing might influence their redox and thrombotic functions. OxLDL binding on platelets correlates with their activation status 5 and inversely with platelet number, suggesting that activation and apoptotic potential of platelets could be influenced by plasma lipids. Consequently, oxidized lipids would expose thrombogenic phosphatidylserine on platelets, propagating assembly of prothrombinase complex, subsequent thrombin generation and thrombosis. The prothrombotic effects of oxLDL could perpetuate from multiple increasingly deposited in the growing thrombus following carotid artery injury in vivo. These evidences exemplify the association between lipid-loaded activated platelets and a prothrombotic effect.
However, at present, we do not provide definite evidence for a direct causative relation. Future interventional studies modulating the platelet lipidome might be a novel strategy to lower the risk for thromboischemic events in high-risk patients. Platelet expression of CXCL12 and its receptors CXCR4-CXCR7 influence disease severity and prognosis in CAD. 13, 14 Enhanced platelet CXCR7 surface expression significantly correlates with that of CXCL12 in ACS patients and is associated with functional recovery. 14 Currently, observed correlation between elevated platelet-oxLDL and CXCR7 surface expression, a receptor known to induce cholesterol uptake in adipose tissue to check plasma cholesterol levels, 15 and previously reported associations between cholesterol-hyperlipidaemia and plasma levels of CXCL12 in CAD, 28 suggest the potential of the CXCL12-CXCR7 axis in influencing circulatory lipid turnover in platelets. Presently, we show that CXCL12 enhances lipid uptake and its thrombotic consequences in vitro. CXCL12 itself being a thrombogenic factor, a resultant cumulative impact of oxLDL and CXCL12 could not be confirmed in vivo and warrants further investigation in genetically deficient (e.g.CXCL12/ CXCR4) hyperlipidaemic mice. Nevertheless, it is tempting to speculate that under hyperlipidaemic condition platelet-derived chemokines might facilitate platelet lipid uptake with resultant pro-oxidative and prothrombotic effects. These novel aspects put platelets to the forefront of circulatory lipid metabolism and atherothrombotic progression. Targeting distinct mechanisms of platelet-lipoprotein 
interplay might offer new therapeutic strategies to prevent progression of CAD.
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